{
    "clinical_study": {
        "@rank": "30126", 
        "arm_group": {
            "arm_group_label": "adult patients treated with Osteoset\u00ae T (tobramycin sulfate)", 
            "description": "10 g or 20 g of Osteoset\u00ae T"
        }, 
        "brief_summary": {
            "textblock": "This study aimed to assess the systemic absorption and disposition of tobramycin in patients\n      treated with a tobramycin-laden bone graft substitute (Osteoset\u00ae T)."
        }, 
        "brief_title": "Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute", 
        "condition": "Orthopedic Operations", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult (> or =18 years old) patients\n\n          -  Treatment with Osteoset\u00ae T\n\n        Exclusion Criteria:\n\n          -  Intravenous tobramycin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "All adult patients treated with Osteoset\u00ae T in our orthopedic surgery department"
            }
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938417", 
            "org_study_id": "Tobramycin cast"
        }, 
        "intervention": {
            "arm_group_label": "adult patients treated with Osteoset\u00ae T (tobramycin sulfate)", 
            "intervention_name": "tobramycin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tobramycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "tobramycin", 
            "bone graft substitute", 
            "pharmacokinetics", 
            "renal failure"
        ], 
        "lastchanged_date": "September 10, 2013", 
        "number_of_groups": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Develop a population pharmacokinetic model for tobramycin in patients treated with an active calcium sulfate bone substitute and to predict tobramycin systemic exposure under various dose and renal function levels.", 
            "measure": "Measurement of systemic tobramycin concentration", 
            "safety_issue": "No", 
            "time_frame": "within 10 days after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938417"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Lausanne Hospitals", 
            "investigator_full_name": "Francoise Livio, MD", 
            "investigator_title": "M\u00e9decin associ\u00e9", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Lausanne Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Lausanne Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2006", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}